Lersivirine

Lersivirine (UK-453061) is potent and selective non-nucleoside reverse transcription inhibitor (NNRTI; IC50=119 nM) with excellent efficacy against NNRTI-resistant viruses. Lersivirine exhibits potent antiretroviral activity against wild-type HIV virus and clinically relevant NNRTI-resistant strains[1].

Product Specifications

CAS Number

[473921-12-9]

Product Name Alternative

UK-453061

UNSPSC

12352005

Hazard Statement

H302

Target

HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Lersivirine.html

Concentration

10mM

Purity

98.38

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CCC1=NN(CCO)C(CC)=C1OC2=CC(C#N)=CC(C#N)=C2

Molecular Formula

C17H18N4O2

Molecular Weight

310.35

Precautions

H302

References & Citations

[1]Mowbray CE, et al. Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. Bioorg Med Chem Lett. 2009 Oct 15;19 (20) :5857-60.|[2]Gregg D Cappon, et al. Developmental toxicity study of lersivirine in mice. Birth Defects Res B Dev Reprod Toxicol. 2012 Jun;95 (3) :225-30.